Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/08/056186
CTRI/2023/08/056186
Not yet recruiting
Phase 4

Efficacy and safety of Netarsudil 0.02% ophthalmic solution in primary angle closure glaucoma in a tertiary care institute, Hisar: Prospective interventional study. - Nil

Maharaja agrasen medical college0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: H401- Open-angle glaucoma

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: H401- Open-angle glaucoma
Sponsor
Maharaja agrasen medical college
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Maharaja agrasen medical college

Eligibility Criteria

Inclusion Criteria

  • •Inclusion Criteria:
  • •1\. Patients of either sex of age \> 40 years.
  • •2\. Clinically diagnosed patients of:
  • •Primary angle closure glaucoma
  • •3\. Able to give informed consent and follow study instructions

Exclusion Criteria

  • •Exclusion Criteria:
  • •1 Patients having known hypersensitivity to any component of the formulation.
  • •2 Previous glaucoma surgery or refractive surgery.
  • •3 Report of ocular injury in either eye.
  • •4 Inability to come for regular follow up.
  • •5 Ocular diseases with inflammation as a manifestation.
  • •6 Use of systemic medication (steroids) that could affect the IOP.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 4
A clinical trial to evaluate efficacy of topical netarsudil in comparison to topical latanoprost in primary angle closure disease spectrumHealth Condition 1: H402- Primary angle-closure glaucoma
CTRI/2023/02/049928Advanced Eye Centre
Completed
Phase 3
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionOcular HypertensionGlaucoma
NCT02246764Aerie Pharmaceuticals93
Completed
Phase 2
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in JapanOpen Angle GlaucomaOcular Hypertension
NCT03844945Aerie Pharmaceuticals215
Completed
Phase 3
Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular HypertensionPrimary Open Angle GlaucomaOcular Hypertension
NCT04620135Aerie Pharmaceuticals245
Completed
Phase 3
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionOpen-angle GlaucomaOcular Hypertension
NCT02558374Aerie Pharmaceuticals708